This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC)

Tipranks - Tipranks - Wed Aug 5, 10:46AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC).

Claim 55% Off TipRanks

Gilead Sciences (GILD)

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Gilead Sciences, with a price target of $130.00. The company’s shares closed last Tuesday at $130.53.

According to TipRanks.com, Richter is a 5-star analyst with an average return of 11.5% and a 49.7% success rate. Richter covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $159.29, implying a 21.5% upside from current levels. In a report issued on July 20, Leerink Partners also downgraded the stock to Hold with a $127.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Danaher (DHR)

Goldman Sachs analyst Evie Koslosky maintained a Buy rating on Danaher yesterday and set a price target of $210.00. The company’s shares closed last Tuesday at $194.69.

According to TipRanks.com, Koslosky is a 1-star analyst with an average return of -2.4% and a 52.6% success rate. Koslosky covers the Healthcare sector, focusing on stocks such as Guardant Health, Mettler-Toledo, and Sotera Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $219.78 average price target, an 11.0% upside from current levels. In a report issued on July 21, TipRanks – Google also upgraded the stock to Buy with a $223.00 price target.

Henry Schein (HSIC)

In a report released today, Brandon Vazquez from William Blair maintained a Hold rating on Henry Schein. The company’s shares closed last Tuesday at $88.60.

According to TipRanks.com, Vazquez is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.2% and a 41.9% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Elanco Animal Health, and Irhythm Technologies. ;'>

Henry Schein has an analyst consensus of Moderate Buy, with a price target consensus of $89.50, a -1.6% downside from current levels. In a report issued on July 20, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $96.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).